After falling almost 30% yesterday, the undervaluation of Bloom Health Partners (CSE: BLMH) has become increasingly apparent.
The company is currently valued at an MC of 5.24 million, while its YTD earnings as of Q3 equate to $24.9 million. Based on its YTD EBITDA, Bloom should be valued well above $70 million.
Bloom is expected to report its fiscal yearly earnings before the end of November. As of now, it is expected that the company will surpass its highest yearly guidance of $28 million. At that point, this undervaluation will be undeniable. Hopefully, these earnings will reach a broader investor base, and we will see a swift correction for Bloom in the next month or so here.
BLMH.c is currently trading at $.11
https://ceo.ca/@newsfile/bloom-health-partners-reports-profitable-fiscal-q3